Skip to main content

South Korea Restricts Gadolinium Use Over Safety Concerns

South Korea Restricts Gadolinium Use Over Safety Concerns

South Korea Restricts Gadolinium Use Over Safety Concerns

Introduction

Health Regulators in South Korea declared a temporary ban on Linear gadolinium agents as lawsuits against gadolinium MRI contrast dyes spike up across the U.S. The ban which will be in effect till the end of the year 2018, applies to a total of 13 linear agents, including Omniscan, Magnevist, and OptiMark informed South Korea's FDA Minister.

Though gadolinium agents are being used in MRI and MRA procedures in the United States, Canada, Japan, and Switzerland, European health regulators put a halt on the use of gadolinium agents in the brain and spinal MRI scans last year.  

Gadolinium agents MultiHance and OptiMark exposure have been reported to cause brain damages and complications to other organs due to gadolinium retention inside the human body. Lawsuits filed against Linear Gadolinium-Based Contrast Agents (GBCA) claim Gadolinium Deposition Disease (GDD) and Nephrogenic Systemic Fibrosis (NSF) as potential adverse effects.

The U.S. FDA issued a black box warning about NSF for 8 MRI gadolinium agents, applicable to individuals with a pre-existing kidney disorder. Gadolinium multidistrict litigation related to NSF (MDL 1909; In Re: Gadolinium Contrast Dyes Products Liability Litigation) was created in 2008, overlooked by Judge Dan Aaron Polster in the Northern District of Ohio.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

Oregon to Get $66M in Sackler Opioid Settlement

Categories: Opioids

Oregon will gain $66 million as part of a nationwide settlement with the Sackler family and Purdue Pharma, the makers of OxyContin. The funds will be used to expand and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!